X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SHASUN PHARMA with Novartis - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs NOVARTIS - Comparison Results

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA NOVARTIS SHASUN PHARMA/
NOVARTIS
 
P/E (TTM) x 123.9 347.8 35.6% View Chart
P/BV x 8.5 17.1 49.8% View Chart
Dividend Yield % 0.2 1.7 13.8%  

Financials

 SHASUN PHARMA   NOVARTIS
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
NOVARTIS
Mar-16
SHASUN PHARMA/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs94982 9.6%   
Low Rs46556 8.2%   
Sales per share (Unadj.) Rs214.2252.9 84.7%  
Earnings per share (Unadj.) Rs5.362.1 8.6%  
Cash flow per share (Unadj.) Rs15.863.3 25.0%  
Dividends per share (Unadj.) Rs1.0010.00 10.0%  
Dividend yield (eoy) %1.41.3 110.0%  
Book value per share (Unadj.) Rs53.3363.6 14.7%  
Shares outstanding (eoy) m56.6231.96 177.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.33.0 10.7%   
Avg P/E ratio x13.112.4 105.8%  
P/CF ratio (eoy) x4.412.2 36.4%  
Price / Book Value ratio x1.32.1 62.0%  
Dividend payout %18.716.1 116.5%   
Avg Mkt Cap Rs m3,95824,580 16.1%   
No. of employees `000NA0.8 0.0%   
Total wages/salary Rs m2,1641,801 120.1%   
Avg. sales/employee Rs ThNM10,748.9-  
Avg. wages/employee Rs ThNM2,395.2-  
Avg. net profit/employee Rs ThNM2,641.1-  
INCOME DATA
Net Sales Rs m12,1278,083 150.0%  
Other income Rs m229829 27.7%   
Total revenues Rs m12,3568,913 138.6%   
Gross profit Rs m1,009234 430.8%  
Depreciation Rs m59437 1,617.4%   
Interest Rs m4152 23,061.1%   
Profit before tax Rs m2301,025 22.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m017 -1.8%   
Extraordinary Inc (Exp) Rs m01,696 0.0%   
Tax Rs m-73752 -9.7%   
Profit after tax Rs m3021,986 15.2%  
Gross profit margin %8.32.9 287.2%  
Effective tax rate %-31.773.4 -43.2%   
Net profit margin %2.524.6 10.1%  
BALANCE SHEET DATA
Current assets Rs m6,88412,678 54.3%   
Current liabilities Rs m8,4562,433 347.6%   
Net working cap to sales %-13.0126.7 -10.2%  
Current ratio x0.85.2 15.6%  
Inventory Days Days6233 188.5%  
Debtors Days Days10822 478.3%  
Net fixed assets Rs m4,97069 7,182.4%   
Share capital Rs m113160 70.9%   
"Free" reserves Rs m2,87511,460 25.1%   
Net worth Rs m3,02011,621 26.0%   
Long term debt Rs m1,8170-   
Total assets Rs m13,34714,400 92.7%  
Interest coverage x1.6570.5 0.3%   
Debt to equity ratio x0.60-  
Sales to assets ratio x0.90.6 161.9%   
Return on assets %5.413.8 38.9%  
Return on equity %10.017.1 58.5%  
Return on capital %13.323.6 56.5%  
Exports to sales %46.40.7 6,224.3%   
Imports to sales %14.218.6 76.6%   
Exports (fob) Rs m5,62260 9,338.0%   
Imports (cif) Rs m1,7281,503 115.0%   
Fx inflow Rs m5,843186 3,136.1%   
Fx outflow Rs m2,1731,821 119.3%   
Net fx Rs m3,669-1,635 -224.5%   
CASH FLOW
From Operations Rs m3982,531 15.7%  
From Investments Rs m-1,635-8,270 19.8%  
From Financial Activity Rs m1,309-386 -339.3%  
Net Cashflow Rs m71-6,125 -1.2%  

Share Holding

Indian Promoters % 39.2 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 3.6 2.0 180.0%  
FIIs % 17.6 1.6 1,100.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 21.5 184.2%  
Shareholders   20,750 41,647 49.8%  
Pledged promoter(s) holding % 12.3 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   STRIDES SHASUN LTD  AJANTA PHARMA  UNICHEM LAB  DR. DATSONS LABS  CADILA HEALTHCARE  

Compare SHASUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Weak Finish to the Week Post Vishal Sikka's Exit as CEO of Infosys(Closing)

Share markets in India witnessed selling pressure, led by slump in shares of Infosys Ltd. after Vishal Sikka resigned as chief executive officer of the country's second-largest software services exporter.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA - ELDER PHARMA COMPARISON

COMPARE SHASUN PHARMA WITH

MARKET STATS